Education
About Us
Working with TipRanks
Follow Us
Agenus (AGEN)
NASDAQ:AGEN
Earnings Data
Report Date
Aug 07, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.99Last Year’s EPS
-2.52Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 12, 2025
|% Change Since: 71.82%
|Next Earnings Date:Aug 07, 2025
Earnings Call Sentiment|Neutral
The earnings call presented significant advancements in leadership, operational efficiency, and promising clinical data for BOT/BAL, despite ongoing financial losses and cash balance concerns. The strategic transactions and new data provide optimism for future growth and regulatory success. However, past regulatory challenges and financial constraints remain points of concern.Company Guidance
During Agenus Inc.'s First Quarter 2025 Earnings Conference Call, the company outlined several key priorities and metrics. They discussed the latest BOT/BAL data showcasing durable responses in cold tumors, emphasized operational efficiencies aimed at reducing operational cash burn to below $50 million annually by the second half of 2025, and mentioned four formal transaction proposals received, including an Emeryville facility sale and two BOT/BAL licensing deals. The company ended Q1 2025 with a cash balance of $18.5 million, down from $40.4 million at the end of 2024, with cash used in operations reduced to $25.6 million from $38.2 million year-over-year. Agenus recognized Q1 2025 revenue of $24.1 million and reported a net loss of $26.4 million, compared to Q1 2024's revenue of $28 million and net loss of $63.5 million. The company is focused on regulatory interactions, having requested a Type B meeting with the FDA, and is optimistic about the potentially favorable new FDA policies that could expedite approval of their therapies.New Leadership and Strategic Hire
Dr. Richard Goldberg, a world-renowned GI-Oncology expert, has joined as the Chief Development Officer to steer regulatory paths for new therapies.
Operational Efficiency and Financial Strategy
Operational cash burn is on track to be cut below $50 million annualized in the second half of 2025. Four formal transaction proposals received, including a significant equity investment at a premium and licensing deals to strengthen the balance sheet.
Positive BOT/BAL Study Results
Consistent and compelling data across different lines of treatment in multiple cold tumors, with presentations at AACR 2025 showing durable responses.
Increased Phase 1 and Phase 2 Follow-Up
Phase 1 trial median follow-up is now 18 months with 123 patients, and Phase 2 trial median follow-up is over 12 months, with substantial data maturity.
AGEN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AGEN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2025 | $2.91 | $3.50 | +20.27% |
Mar 11, 2025 | $2.15 | $2.05 | -4.65% |
Nov 12, 2024 | $3.90 | $3.10 | -20.51% |
Aug 08, 2024 | $5.08 | $5.28 | +3.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Agenus (AGEN) report earnings?
Agenus (AGEN) is schdueled to report earning on Aug 07, 2025, TBA Not Confirmed.
What is Agenus (AGEN) earnings time?
Agenus (AGEN) earnings time is at Aug 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AGEN EPS forecast?
AGEN EPS forecast for the fiscal quarter 2025 (Q2) is -0.99.